(Update to add stock movement in the headline and fifth paragraph)
AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported Thursday fiscal 2026 earnings of NZ$0.14 per share, up from NZ$0.11 a year earlier.
Revenue for the 12 months ended March 31 was NZ$254.7 million, compared with NZ$208 million a year earlier.
The company expects to continue its growth trajectory in fiscal 2027 as it works toward achieving its revenue target of at least NZ$300 million, with operating profit projected to range between NZ$28 million and NZ$32 million.
The board declared a final dividend of NZ$0.025 per share, up from NZ$0.018 a year earlier, payable July 3 to shareholders on record as of June 19.
Its shares rose over 11% in recent trading on the Australian bourse and over 9% on the New Zealand bourse, reaching an over three-year high.